TRAILR1/TNFRSF10A Antibody [Unconjugated]

Western blot shows lysates of TF‑1 human erythroleukemic cell line. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human TRAIL R1/TNFRSF10A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF347) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for TRAIL R1/TNFRSF10A at approximately 50 kDa (as indicated). This experiment was conducted under reducing conditions.

In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera (Catalog # 347‑DR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375‑TL) induced cytotoxicity in the L‑929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (12 ng/mL) activity elicited by Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human TRAIL R1/TNFRSF10A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF347). The ND50 is typically 0.02‑0.055 µg/mL.

TRAIL R1/TNFRSF10A was detected in immersion fixed paraffin-embedded sections of human brain using Goat Anti-Human TRAIL R1/TNFRSF10A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF347) at 10 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in neurons. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

B3GNT2 disrupts ligand–receptor interactions between tumor and T cells.a Cell survival against T cell cytotoxicity (top) and T cell IFN gamma secretion (bottom) in A375 cells overexpressing B3GNT2 or GFP that have been treated with different concentrations of kifunensine. Kifunensine was used to pretreat A375 cells and was present during co-culture with T cells at E:T ratio of 3. Kifunensine-treated cells that were co-cultured with ESO T cells were compared to kifunensine-treated cells cultured in parallel without T cells to determine percent survival. N = 6. Two-tailed t tests were performed. b Tomato lectin IP of A375 cells overexpressing GFP or B3GNT2 followed by western blot for different B3GNT2 target proteins. 2% of the input and no lectin IP controls are shown. Data are representative of two independent experiments. c Western blots of A375 cells overexpressing B3GNT2 or GFP that were treated with kifunensine (KIF) or benzyl-2-acetamido-2-deoxy-alpha -D-galactopyranoside (BAG) to remove N- or O-glycosylation respectively. Data are representative of two independent experiments. d Histograms (top) and corresponding median fluorescence intensity (MFI; bottom) showing binding of recombinant T cell proteins to A375 cells measured by flow cytometry. A375 cells were overexpressing GFP or B3GNT2 and treated with KIF or BAG. N = 3. Two-tailed t tests were performed. e Schematic showing the tumor cell surface ligands and receptors modified by B3GNT2 to disrupt interactions with T cells that mediate cytotoxicity. All values are mean ± s.e.m. ns not significant. Source data are provided in Source Data 4. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35338135), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: WB, IHC, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

TRAILR1/TNFRSF10A Antibody [Unconjugated] Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human TRAIL R1/TNFRSF10A
  Ala24-Asn239
  Accession # AAC51226
• Specificity: Detects human TRAIL R1/TNFRSF10A in direct ELISAs and Western blots. In Western blots, approximately 10% cross-reactivity with recombinant human (rh) TRAIL R2 is observed and less than 1% cross-reactivity with rhTRAIL R3 and rhTRAIL R4 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: TNFRSF10A
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-15 ug/mL
  • Neutralization 0.02-0.055 ug/mL
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TRAILR1/TNFRSF10A Antibody [Unconjugated]

• APO2
• CD261 antigen
• CD261
• cytotoxic TRAIL receptor
• Death receptor 4
• DR4 TRAIL receptor 1
• DR4
• TNF-related apoptosis inducing ligand receptor 1
• TNF-related apoptosis-inducing ligand receptor 1
• TNFRSF10A
• TRAIL R1
• TRAILR1
• TRAIL-R1
• TRAILR-1
• TRAILR1MGC9365
• tumor necrosis factor receptor superfamily member 10A
• tumor necrosis factor receptor superfamily, member 10a

Background

Human TRAIL R1, also called DR4, is a type 1, TNF R family, membrane protein which is a receptor for TRAIL (APO2 ligand). In the TNF superfamily nomenclature, TRAIL RI is referred to as TNFRSF10A. TRAIL R1 cDNA encodes a 468 amino acid residue precursor protein containing extracellular cysteine-rich domains, a transmembrane domain and a cytoplasmic death domain. Among the TNF receptor family proteins, TRAIL R1 is most closely related to TRAIL R2/DR5, sharing 55% amino acid sequence identity. Binding of trimeric TRAIL to TRAIL R1 induces apoptosis. The induction of apoptosis likely requires oligomerization of the receptor. The human TRAIL R1/Fc chimera neutralizes the ability of TRAIL to induce apoptosis. Besides TRAIL R1, an additional TRAIL R2/DR5, which tranduces apoptosis signal, and two TRAIL decoy receptors, which antagonize TRAIL-induced apoptosis, have been reported.

1. Pan, G. et al. (1997) Science 276:111.
2. Golstein, P. (1997) Curr. Biol. 7:R750.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for TRAILR1/TNFRSF10A Antibody (AF347)(39)

Publications using AF347

• R Yerbes, R Mora-Molin, FJ Fernández-, L Hiraldo, A López-Riva, C Palacios Limiting glutamine utilization activates a GCN2/TRAIL-R2/Caspase-8 apoptotic pathway in glutamine-addicted tumor cells Cell Death & Disease, 2022-10-27;13(10):906. 2022-10-27 [PMID: 36302756] (Western Blot, Human)
• J Joung, PC Kirchgatte, A Singh, JH Cho, SP Nety, RC Larson, RK Macrae, R Deasy, YY Tseng, MV Maus, F Zhang CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity Nature Communications, 2022-03-25;13(1):1606. 2022-03-25 [PMID: 35338135] (Western Blot, Human)
• M Kopczynski, M Statkiewic, M Cybulska, U Kuklinska, K Unrug-Biel, Z Sandowska-, A Grochowska, M Gajewska, M Kulecka, J Ostrowski, M Mikula Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer Models International Journal of Molecular Sciences, 2021-03-19;22(6):. 2021-03-19 [PMID: 33808900] (ICC, Human)
• JD Yoo, SM Bae, J Seo, IS Jeon, SMP Vadevoo, SY Kim, IS Kim, B Lee, S Kim Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy Sci Rep, 2020-11-17;10(1):19997. 2020-11-17 [PMID: 33203916] (Bioassay, Human)
• Reema Baskar, Harris G Fienberg, Zumana Khair, Patricia Favaro, Sam Kimmey, Douglas R Green et al. TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosis Life Science Alliance 2019-12-01 [PMID: 31704709] (Flow Cytometry, Human)
• Reema Baskar, Harris G Fienberg, Zumana Khair, Patricia Favaro, Sam Kimmey, Douglas R Green et al. TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosis Life Science Alliance 12/1/2019 [PMID: 31704709]
• S Serrano-Sa, C Palacios, D Delgado-Be, L López-Jimé, A Garcia-Dia, Y Soto-Serra, JI Casal, RA Bartolomé, JL Fernández-, A López-Riva, FJ Oliver PIM kinases mediate resistance of glioblastoma cells to TRAIL by a p62/SQSTM1-dependent mechanism Cell Death Dis, 2019-01-18;10(2):51. 2019-01-18 [PMID: 30718520] (Western Blot, Human)
• Y Shlyakhtin, V Pavet, H Gronemeyer Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells Cell Death Dis, 2017-08-31;8(8):e3025. 2017-08-31 [PMID: 29048428] (Immunoprecipitation, Human)
• V Liapis, A Zysk, M DeNichilo, I Zinonos, S Hay, V Panagopoul, A Shoubridge, C Difelice, V Ponomarev, W Ingman, GJ Atkins, DM Findlay, ACW Zannettino, A Evdokiou Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma Cancer Med, 2017-08-10;0(0):. 2017-08-10 [PMID: 28799237] (Western Blot, Human)
• C Liang, Y Xu, G Li, T Zhao, F Xia, G Li, D Zhang, J Wu Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis Onco Targets Ther, 2017-01-18;10(0):417-428. 2017-01-18 [PMID: 28176915] (Neutralization, Human)
• Zinonos I, Labrinidis A, Liapis V, Hay S, Panagopoulos V, Denichilo M, Ponomarev V, Ingman W, Atkins G, Findlay D, Zannettino A, Evdokiou A Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs). Anticancer Res, 2014-12-01;34(12):7007-20. 2014-12-01 [PMID: 25503127] (Flow Cytometry, Human)
• Jun-jie Chen, Constantinos M. Mikelis, Yaqin Zhang, J. Silvio Gutkind, Baolin Zhang TRAIL induces apoptosis in oral squamous carcinoma cells: a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5 Oncotarget 2/23/2013 [PMID: 23470485]
• Jun-Jie Chen, H.-C. Jennifer Shen, Leslie A. Rivera Rosado, Yaqin Zhang, Xu Di, Baolin Zhang Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells Oncotarget 8/19/2012 [PMID: 22909995]
• Elias A, Siegelin MD, Steinmuller A, von Deimling A, Lass U, Korn B, Mueller W Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas. Clin. Cancer Res., 2009-08-25;15(17):5457-65. 2009-08-25 [PMID: 19706813] (Neutralization, Human)
• Park SJ, Sohn HY, Yoon J, Park SI Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells. Cell. Signal., 2009-05-24;21(10):1495-503. 2009-05-24 [PMID: 19470406] (Flow Cytometry, Human)
• Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Biochem. Pharmacol., 2009-01-24;77(8):1328-36. 2009-01-24 [PMID: 19426671] (Western Blot, Human)
• Siegelin MD, Gaiser T, Habel A, Siegelin Y Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2. Cancer Lett., 2009-04-26;283(2):230-8. 2009-04-26 [PMID: 19398149] (Western Blot, Human)
• Festuccia C, Gravina GL, D'Alessandro AM, Millimaggi D, Di Rocco C, Dolo V, Ricevuto E, Vicentini C, Bologna M Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells. Int. J. Oncol., 2008-08-01;33(2):381-8. 2008-08-01 [PMID: 18636160] (Western Blot, Human)
• Wu CH, Kao CH, Safa AR TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5. Hum. Gene Ther., 2008-07-01;19(7):731-43. 2008-07-01 [PMID: 18476767] (Neutralization, Human)
• Kim EH, Yoon MJ, Kim SU, Kwon TK, Sohn S, Choi KS Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation. Cancer Res., 2008-01-01;68(1):266-75. 2008-01-01 [PMID: 18172319] (Flow Cytometry, Human)
• Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser KB, Okamoto K, Ganslmayer M, Hahn EG, Herold C, Ocker M Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. Int. J. Oncol., 2007-12-01;31(6):1391-402. 2007-12-01 [PMID: 17982666] (Western Blot, Human)
• Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Biochem. Pharmacol., 2006-05-04;72(3):293-307. 2006-05-04 [PMID: 16753135] (Flow Cytometry, Neutralization, Human)
• Masood R, Kumar SR, Sinha UK, Crowe DL, Krasnoperov V, Reddy RK, Zozulya S, Singh J, Xia G, Broek D, Schonthal AH, Gill PS EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Int. J. Cancer, 2006-09-15;119(6):1236-48. 2006-09-15 [PMID: 16615113] (Western Blot, Human)
• Lane D, Cote M, Grondin R, Couture MC, Piche A Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3. Mol. Cancer Ther., 2006-03-01;5(3):509-21. 2006-03-01 [PMID: 16546965] (Western Blot, Human)
• Roux S, Lambert-Comeau P, Saint-Pierre C, Lepine M, Sawan B, Parent JL Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Biochem. Biophys. Res. Commun., 2005-07-22;333(1):42-50. 2005-07-22 [PMID: 15936719] (IHC-P, Human)
• Morel J, Audo R, Hahne M, Combe B Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J. Biol. Chem., 2005-01-31;280(16):15709-18. 2005-01-31 [PMID: 15684417] (Flow Cytometry, Human)
• Ricci-Vitiani L, Pedini F, Mollinari C, Condorelli G, Bonci D, Bez A, Colombo A, Parati E, Peschle C, De Maria R Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death. J. Exp. Med., 2004-11-15;200(10):1257-66. 2004-11-15 [PMID: 15545353] (Flow Cytometry, Human)
• Chopin V, Slomianny C, Hondermarck H, Le Bourhis X Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors&#039; signaling and requires P21(waf1). Exp. Cell Res., 2004-08-15;298(2):560-73. 2004-08-15 [PMID: 15265702] (Western Blot, Human)
• Ryan LA, Peng H, Erichsen DA, Huang Y, Persidsky Y, Zhou Y, Gendelman HE, Zheng J TNF-related apoptosis-inducing ligand mediates human neuronal apoptosis: links to HIV-1-associated dementia. J. Neuroimmunol., 2004-03-01;148(1):127-39. 2004-03-01 [PMID: 14975593] (IHC-Fr, Human)
• Nakajima H, Yanase N, Oshima K, Sasame A, Fukazawa S, Takata R, Mukai K, Yamashina A, Mizuguchi J Enhanced expression of the apoptosis inducing ligand TRAIL in mononuclear cells after myocardial infarction. Jpn Heart J, 2003-11-01;44(6):833-44. 2003-11-01 [PMID: 14711179] (IHC-P, Human)
• Ruiz de Almodovar C, Ruiz-Ruiz C, Rodriguez A, Ortiz-Ferron G, Redondo JM, Lopez-Rivas A Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site. J. Biol. Chem., 2003-11-17;279(6):4093-101. 2003-11-17 [PMID: 14623878] (Western Blot, Human)
• Secchiero P, Milani D, Gonelli A, Melloni E, Campioni D, Gibellini D, Capitani S, Zauli G Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells. J. Leukoc. Biol., 2003-08-01;74(2):223-32. 2003-08-01 [PMID: 12885939] (Neutralization, Human)
• Voelkel-Johnson C An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Cancer Biol. Ther., 2003-05-01;2(3):283-90. 2003-05-01 [PMID: 12878867] (Neutralization, Human)
• Mouzakiti A, Packham G Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt&#039;s lymphoma cell lines. Br. J. Haematol., 2003-07-01;122(1):61-9. 2003-07-01 [PMID: 12823346] (Western Blot, Human)
• Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ. Res., 2003-03-20;92(7):732-40. 2003-03-20 [PMID: 12649264] (Flow Cytometry, Human)
• Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, Miyazoe S, Nakagawa Y, Ishikawa H, Hamasaki K, Nakata K, Ishii N, Eguchi K Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene, 2003-03-20;22(11):1653-62. 2003-03-20 [PMID: 12642868] (Flow Cytometry, Human)
• Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene, 2002-08-22;21(37):5673-83. 2002-08-22 [PMID: 12173037] (Flow Cytometry, Human)
• Hueber A, Aduckathil S, Kociok N, Welsandt G, Dinslage S, Kirchhof B, Esser PJ Apoptosis-mediating receptor-ligand systems in human retinal pigment epithelial cells. Chin. Med. J., 2002-06-20;240(7):551-6. 2002-06-20 [PMID: 12136286] (IHC-Fr, Human)
• Bretz JD, Mezosi E, Giordano TJ, Gauger PG, Thompson NW, Baker JR Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells. Cell Death Differ., 2002-03-01;9(3):274-86. 2002-03-01 [PMID: 11859410] (Flow Cytometry, Human)

Bioinformatics

• Gene Symbol: TNFRSF10A
• Uniprot:
  • AAC51226()